|View printer-friendly version|
Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
A live audio webcast and replay will be available in the Investors section on the company’s website at www.cidara.com.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of serious invasive fungal infections. CD101 topical is the first and only agent of its class being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient's immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the effectiveness, safety, and other attributes of CD101 IV, CD101 topical and CD201 and their potential to treat infections, as well as the potential for the Cloudbreak program to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
Robert H. Uhl Westwicke Partners, LLCManaging Director (858) 356-5932 email@example.com MEDIA CONTACT: Mike Beyer Sam Brown Inc.(312) 961-2502 firstname.lastname@example.org